Anagrelide Capsules

[07 April 2016]

Products Affected - Description

Anagrelide Hydrochloride oral capsule, Teva
0.5 mg, 100 count (NDC 00172-5241-60)
1 mg, 100 count (NDC 00172-5240-60)

Reason for the Shortage

  • Mylan Pharmaceuticals discontinued anagrelide capsules in 2015.
  • Teva cannot provide a reason for the shortage.

Available Products

Agrylin oral capsule, Shire
0.5 mg, 100 count (NDC 54092-0063-01)

Estimated Resupply Dates

Teva has anagrelide 0.5 mg and 1 mg capsules on back order and the company estimates a release date of late-May 2016.

Related Shortages


April 7, March 10, February 16, January 6, 2016, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
ASHP Product Listing